Biogen has agreed to acquire Apellis Pharmaceuticals after an extended negotiation process. The company also entered a collaboration with Alloy Therapeutics focused on antisense drug development using ...
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target ...
Biogen (BIIB) partners with Alloy Therapeutics for antisense oligonucleotide platform access. RBC cuts price target to $213 while maintaining Outperform.
At first, researchers thought that antisense drugs would prove so specific there would be few side effects. But toxicity-related problems did arise in initial animal studies of antisense drugs in the ...
Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...
AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration ...
The Food & Drug Administration has granted Isis Pharmaceuticals and its partner Genzyme approval to market Kynamro, a once-weekly subcutaneous injection to lower lipid levels in people with a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results